Author: admin

Tax Expert Carrie Kiser of Kiser Tax and Accounting in Tempe, Arizona, Co-Authors New Bestselling Tax Reduction Book for Small Business Owners Entitled “DeTaxify Your Life”

Tax Expert Carrie Kiser of Kiser Tax and Accounting in Tempe, Arizona, Co-Authors New Bestselling Tax Reduction Book for Small Business Owners Entitled "DeTaxify Your Life"

“I work with small business owners to uncover tax strategies they didn’t know existed, the same proactive approach I share in “DeTaxify Your Life” to help reduce tax liability and improve cash flow.” – Carrie Kiser, Kiser Tax and Accounting
Carrie Kiser, a Phoenix, Arizona area, tax accountant, Enrolled Agent, and business tax consultant at Kiser Tax and Accounting in Tempe, co-authors a bestselling book, “DeTaxify Your Life,” focusing on proactive tax planning, tax reduction strategies, bookkeeping, and small business tax services. Known for providing strategic planning, tax preparation, and year-round implementation, Kiser helps entrepreneurs reduce tax liability, improve cash flow, and achieve stronger financial results.

Tempe, AZ – Carrie Kiser, a leading tax accountant in Tempe, AZ, business tax consultant, and founder of Kiser Tax & Accounting, has reached #1 bestseller status as a co-author of the newly released book, “DeTaxify Your Life: Trim the Fat from Your Tax Bill and Put More Money in Your Pocket.” Kiser is widely known for providing proactive tax planning services that help small business owners reduce tax burdens and increase profitability.

Released on April 16, 2026, the book surged to bestseller status and the #1 spot on Amazon’s Taxation, Bookkeeping, and Small Business Taxes lists on its first day. The collaboration features 17 of the country’s premier Certified Tax Coaches, each sharing proactive frameworks designed to help small business owners, entrepreneurs, and individuals to potentially save thousands of dollars on their taxes.

The book addresses a critical gap in the market: while most small business owners rely on “rearview mirror” tax preparation, this guide provides a proactive roadmap to legally and significantly lower tax liabilities before the year ends across a variety of different areas.

“Business owners looking for tax help don’t often realize how much they’re leaving on the table,” says Carrie Kiser of Kiser Tax and Accounting. “With proactive tax planning, we help clients uncover opportunities to reduce taxes and improve cash flow year-round,” Carrie Kiser added.

In her contribution, Kiser draws on her experience as a Certified Tax Coach and Enrolled Agent in Tempe, Arizona, to simplify complex financial challenges for business owners and individuals. Her work reflects the same proactive approach she delivers through her tax planning, preparation, and bookkeeping services at Kiser Tax and Accounting.

The book covers key topics, including Modern Reform Strategies: Navigating the most recent legislative changes, including the One Big Beautiful Bill Act. Proactive Planning: How to avoid the common compliance mistakes that lead to overpayment. Overlooked Strategies and Deductions: Identifying legal paths to maximize tax-free income.

“DeTaxify Your Life” is now available for purchase on Amazon.

About Carrie Kiser

Carrie Kiser is a Certified Tax Coach and Accredited Small Business Consultant who founded Kiser Tax and Accounting to provide proactive accounting support, advice, and strategies that help small business owners keep more of what they earn while working toward their individual definitions of success.

Since 2017, Carrie’s life’s work has been to educate and empower entrepreneurs to take control of their finances, highlighting their strengths while identifying areas for improvement. She and her team design customized tax strategies and implement them through year-round bookkeeping support, as needed, to provide direction and accountability.

For more information please visit:

Google Maps/Profile

Amazon

Linkedin

Media Contact
Company Name: Kiser Tax and Accounting
Contact Person: Carrie Kiser, Certified Tax Coach
Email: Send Email
Phone: (480) 712-8122
Address:4450 S Rural Rd E225 Tempe, AZ 85282, USA
City: Tempe
State: Arizona
Country: United States
Website: https://kiser.tax/

Liz Carroll’s New Book, Rich & Radiant, Featured in Special Amazon Flash Sale

Liz Carroll, Master Financial Coach, Certified Life Coach, yoga and meditation instructor, and founder of the Mindful Money Method, announces a special Amazon Flash Sale for her new book, Rich & Radiant: The High-Performing Woman’s Guide to Freedom, Fulfillment, and a New Definition of Wealth.

Written for high-achieving women who appear successful on the outside but still feel uncertain, disconnected, or anxious about money, Rich & Radiant offers a compassionate and practical path toward financial calm, confidence, and intentional living. Carroll guides readers through a holistic approach to money that blends math, mindset, and mindfulness, helping women move from avoidance and fear to awareness, clarity, and vision.

“Many women are earning well, achieving a lot, and still quietly wondering if they are doing it right,” says Carroll. “This book is an invitation to stop living on financial autopilot and begin creating a relationship with money that feels calm, aligned, and empowering.”

In Rich & Radiant, Carroll teaches women how to face their “math of the moment,” build financial safety nets, rewrite limiting money stories, define their own financial independence number, and align their money with what matters most to them. The book also explores how fear, guilt, comparison, and old inherited beliefs can quietly shape financial decisions, and how women can replace those patterns with self-trust, clarity, and mindful action.

At the heart of the book is Carroll’s belief that wealth is more than accumulation. True wealth includes freedom, fulfillment, generosity, emotional wellness, meaningful experiences, and the ability to live with intention. Through personal stories, client examples, practical exercises, and empowering reframes, Rich & Radiant helps readers create a financial life that supports who they are becoming.

“This is not a book about restriction or shame,” Carroll says. “It is about helping women feel safe enough to look honestly at their money, powerful enough to make aligned decisions, and free enough to live richly and radiantly right now, not someday.”

Don’t miss your chance to grab Rich & Radiant at a special price during the Amazon Flash Sale: https://www.amazon.com/dp/B0H1NHBMTH

Learn more about Liz Carroll and her workshops at: www.BeRichandRadiant.com.

About Liz Carroll

Liz Carroll is a lifelong student and teacher of making mindful money moves. Once believing she was “bad with money,” Liz did the work to rewrite her money story, releasing limiting beliefs about how a woman can earn, spend, and save. That shift led her to financial independence and an early retirement from her corporate IT sales career.

Now, in her encore career, Liz helps women experience calm confidence with their finances by unpacking and transforming their own money stories. She brings order to chaos and clarity to confusion, illuminating the emotional side of personal finance with compassion and wisdom. Through her signature Mindful Money Method, a holistic blend of math, mindset, and mindfulness, Liz guides women toward lasting change through small, consistent actions that create freedom and fulfillment.

Liz is a Master Financial Coach (Ramsey Solutions), Certified Life Coach (The Life Coach School), and 200-RYT Yoga & Meditation Instructor (Purna Yoga College). She lives on the Oregon Coast with her husband, where their adult children and grandchildren visit often.

Media Contact
Company Name: Imperial Action
Contact Person: Media Manager
Email: Send Email
Phone: (630) 923-5425
Country: United States
Website: http://imperialaction.com

Virtual Reality Technology to Help People in Arkansas With Their Mental Health

An Arkansas mental health clinic is using virtual reality to help people reduce their stress levels and regulate their emotions.

PsychologyWorks PLLC, which is based in Bentonville, Northwest Arkansas, has officially partnered with Healium, a VR‑based biofeedback platform used in clinical, medical, and high‑performance settings. People will be able to experience immersive VR environments, which respond to how they are feeling using real-time physiological data like their heart rate and heart rate variability.

The clinic is the only setting in Arkansas which offers this technology, other than Veterans Affairs (VA). And PsychologyWorks will be integrating Healium into its psychotherapy for emotional regulation, trauma stabilization and neurodivergent‑affirming care.

Licensed clinical psychologist Dr Stephanie Steele-Wren is the founder and owner of PsychologyWorks and believes the technology will be highly effective in helping people deal with stress. She says: “Healium is basically a way to make your nervous system visible. You put on a VR headset and a small wearable that reads your heart rate and your HRV.

“As your physiology shifts even slightly, the VR environment shifts with you. If you settle, breathe, or ground, the scene calms with you. If your stress rises, the environment reflects that too.”

And Dr Steele-Wren, who specializes in working with neurodivergent people, says the technology is extremely helpful for those who may find it difficult to identify or describe how they are feeling.

She adds: “It takes something most people cannot feel or describe, their internal state, and turns it into something they can literally watch change in front of them. For neurodivergent clients, trauma survivors, kids, teens, and adults who do not regulate through talking alone or even at all, this is huge.”

There have been multiple published studies, including research carried out with Mayo Clinic into the value of using virtual reality to reduce stress levels and anxiety. Researchers found the technology reduced people’s stress markers, improved their HRV and helped decrease distress quickly.

Dr Steele-Wren says: “Bringing this into PsychologyWorks felt like the right move for the community I serve. Healium is backed by research and what matters to me clinically is how accessible it is. It meets people where they actually are, sensorily, visually and experientially.”

For more details on PsychologyWorks, visit www.psychologyworkspllc.com and to find out about Healium, visit www.tryhealium.com

Media Contact
Company Name: Dauntless PR
Contact Person: Luana Ribeira
Email: Send Email
Phone: 03300434102
Country: United Kingdom
Website: http://dauntlesspr.com

Healing with Sacred Geometry – Amanda Slade Newly Released Book Offers a Highly Effective Spiritual Transformation Framework

Long Beach, CA, USA – May 28, 2026 – Renowned Transformation Expert, Spiritual Mentor, and best-selling author Amanda Slade has officially released her new book, A 30-Day Soul’s Journey: Your Path of Awakening—a powerful 30-day transformational guide designed to help readers awaken, heal, and align with their Soul’s purpose, plan, and path so they can operate, create, and live from a higher level of awareness, understanding, and conscious choice.

Rooted in Amanda’s internationally recognized The Diamond Co-Creative System®—a 25-year, tried-and-proven transformational energy technology—this immersive journey offers readers a practical, spiritually grounded pathway to move from survival, self-doubt, and unconscious patterns into embodied transformation, conscious living, and personal and professional evolution.

Through four progressive phases—Transformation, Alignment, Manifestation, and Expansion—readers are guided one day at a time through spiritual principles, energetic awareness, powerful reflections, Soul-guided insights, and Amanda’s signature Diamond Co-Creation Codes, all designed to support deep healing, inner coherence, and measurable life transformation and results.

“For many people, awakening begins when what once worked no longer aligns with who they are becoming,” says Slade. “This book was created for the moment when your Soul becomes louder than old programming, limiting beliefs, and survival-based patterns.”

A 30-Day Soul’s Journey helps readers turn awakening into 5th Dimensional living—a new way of being, living, leading, and creating through the flow of Love, joy, creativity, prosperity, intuition, and Soul alignment.

For more than 25 years, Amanda Slade has helped thousands of seekers, entrepreneurs, creatives, coaches, healers, executives, leaders, and visionaries heal and transform energetic blocks and patterns, manifest Soul-aligned outcomes, and step into greater purpose, fulfillment, prosperity, leadership, and legacy.

In addition to being a best-selling author and the creator of The Diamond Co-Creative System®, Amanda is featured in the Pillars of Power movie alongside Dr. Joe Vitale, John Assaraf, Lisa Nichols, and other thought leaders from The Secret, sharing insights on transformation, vibrational alignment, and the deeper spiritual principles behind extraordinary success.

Amanda Slade is available for interviews.

A 30-Day Soul’s Journey: Your Path of Awakening is now available on Amazon.com.

Book Preview: https://mybook.to/a30DaySoulsJourney

About Amanda Slade: https://cocreateyoursuccess.com/aboutamanda

Media Contact
Company Name: Co-Create Your Success
Contact Person: Amanda Slade
Email: Send Email
Phone: 415-426-9764
Country: United States
Website: https://cocreateyoursuccess.com

Dr. Yorell Manon-Matos Opens 2027 Scholarship Applications for Healthcare Students

Dr. Yorell Manon-Matos Opens 2027 Scholarship Applications for Healthcare Students

SIOUX FALLS, S.D. – Dr. Yorell Manon-Matos, a distinguished board-certified hand surgeon and a prominent figure in medical education, is pleased to announce the official opening of the 2027 application cycle for the Dr. Yorell Manon-Matos Scholarship for Healthcare Students. This initiative represents a significant investment in the next generation of medical professionals, offering financial support to those who demonstrate academic excellence and a steadfast commitment to the advancement of patient care.

As the healthcare landscape continues to evolve, the need for compassionate, highly skilled, and dedicated professionals has never been greater. Dr. Manon-Matos, who currently serves as an attending surgeon at Avera Health in Sioux Falls, South Dakota, established this scholarship to help alleviate the financial burdens that often accompany a rigorous medical education. With over 15 years of experience in hand and microsurgery, Dr. Manon-Matos understands firsthand the challenges of the journey and is committed to fostering an environment where talented students can thrive regardless of their economic background.

The scholarship is open to undergraduate and graduate students currently enrolled at accredited institutions across the United States. Recognizing that healthcare is a multidisciplinary effort, eligibility extends to a wide array of fields, including medicine, nursing, dentistry, pharmacy, public health, and other related healthcare disciplines. By casting a wide net, the program seeks to support a diverse cohort of future leaders who will collectively shape the future of global health systems.

To be considered for the award, applicants must maintain a minimum cumulative GPA of 3.0 on a 4.0 scale, reflecting a consistent record of academic achievement. In addition to academic merit, the selection committee places a heavy emphasis on financial need and personal character. A central requirement of the application is a 750-word essay. This essay serves as a platform for students to articulate their professional ambitions, discuss the financial obstacles they have encountered, and describe how they intend to make a meaningful impact in their chosen field. Dr. Manon-Matos is particularly interested in candidates who view healthcare not just as a career, but as a calling rooted in service and innovation.

“Education is the foundation of progress in medicine,” says Dr. Yorell Manon-Matos. “Through this scholarship, we aim to empower students who possess the drive and the heart to transform patient outcomes. Our goal is to ensure that the brightest minds in healthcare are given the opportunity to succeed, bringing fresh perspectives and renewed energy to the medical community.”

The deadline for all application materials is February 15, 2027. Following a rigorous and comprehensive review process, the scholarship recipient will be officially announced on March 15, 2027. The award is presented as a one-time financial contribution intended to assist with tuition, books, and other essential educational expenses.

About Dr. Yorell Manon-Matos

Dr. Yorell Manon-Matos is a board-certified hand surgeon with an extensive background in clinical practice and medical education. He earned his medical degree from Dartmouth Medical School, followed by a general surgery residency at Baystate Medical Center and a specialized fellowship in hand and microsurgery at the Christine M. Kleinert Institute. Currently practicing at Avera Health, he is a dedicated mentor to medical students and residents, consistently advocating for the integration of clinical excellence and compassionate care.

Media Contact
Company Name: Dr. Yorell Manon-Matos Scholarship for Healthcare Students
Contact Person: Dr. Yorell Manon-Matos
Email: Send Email
City: SIOUX FALLS
State: South Dakota
Country: United States
Website: https://dryorellmanonmatosscholarship.com

Christopher Balter Announces Undergraduate Community Impact Scholarship

Christopher Balter Announces Undergraduate Community Impact Scholarship

Palm Bay, Florida – The Christopher Balter Second Chance Community Impact Scholarship officially announces its national scholarship opportunity for undergraduate students dedicated to creating meaningful and sustainable change within communities through leadership, planning, public administration, and public service initiatives.

Founded by Christopher Balter, the scholarship reflects a long-standing commitment to supporting future professionals who seek to address real-world community challenges through strategic thinking, collaboration, and sustainable development practices. The program is designed to recognize undergraduate students who demonstrate both academic dedication and a clear passion for improving the social and structural conditions of communities across the United States.

The Christopher Balter Second Chance Community Impact Scholarship offers a one-time award of $1,000 to a qualifying undergraduate student pursuing or intending to pursue a career connected to community impact, urban planning, public administration, nonprofit leadership, public policy, or related fields focused on public service and development.

Applications for the Christopher Balter Second Chance Community Impact Scholarship remain open through September 15, 2026. The selected scholarship recipient will be announced on October 15, 2026.

As part of the application process, eligible students must submit an original essay between 750 and 1,000 words responding to the following prompt:

“Describe a community challenge that you are passionate about improving. How would you approach creating a sustainable and long-term solution, and how does your future career path align with this vision?”

The scholarship committee evaluates submissions based on clarity, originality, critical thinking, leadership potential, and a demonstrated commitment to long-term community-focused solutions. The Christopher Balter Second Chance Community Impact Scholarship places strong emphasis on practical ideas that reflect sustainable development principles and measurable social impact.

According to scholarship organizers, the initiative aims to encourage the next generation of professionals who recognize the importance of thoughtful planning, civic leadership, and responsible development in shaping resilient communities.

Christopher Balter continues to advocate for collaborative approaches to planning and development through his professional work and scholarship efforts. His experience in urban planning, development services, regulatory strategy, and community engagement directly informs the mission behind the Christopher Balter Second Chance Community Impact Scholarship.

Throughout his career, Christopher Balter has led initiatives involving long-range planning, land development review, regulatory modernization, and infrastructure-focused community projects. His leadership background includes directing planning and development services while also overseeing major policy and strategic planning efforts designed to align growth with long-term community needs.

Today, through CMB Planning Consultants, Christopher Balter provides consulting services related to land use planning, rezoning strategies, urban design, and development consultation. The Christopher Balter Second Chance Community Impact Scholarship extends this mission into higher education by supporting students who aspire to become future leaders in community-centered professions.

The scholarship remains open to undergraduate students nationwide and is not limited by geographic region. Students from diverse academic backgrounds connected to public service and community improvement are encouraged to apply.

Additional information regarding eligibility requirements, essay guidelines, application deadlines, and submission instructions is available on the official scholarship website.

About the Christopher Balter Second Chance Community Impact Scholarship

The Christopher Balter Second Chance Community Impact Scholarship is a national academic initiative established by Christopher Balter to support undergraduate students pursuing careers related to community development, urban planning, public administration, nonprofit leadership, and public service. The scholarship recognizes students committed to developing sustainable solutions for modern community challenges while promoting leadership, civic engagement, and long-term social impact.

Media Contact
Company Name: Christopher Balter Second Chance Community Impact Scholarship
Contact Person: Christopher Balter
Email: Send Email
City: Palm Bay
State: Florida
Country: United States
Website: https://christopherbalterscholarship.com

Dr. Jacqueline Youtsos Launches New Medical Scholarship for Undergraduate and Medical Students

Dr. Jacqueline Youtsos Launches New Medical Scholarship for Undergraduate and Medical Students

Dr. Jacqueline Youtsos Scholarship for Medical Students

PITTSBURG, KS – The Dr. Jacqueline Youtsos Scholarship today announced its official launch, offering a $1,000 award to undergraduate and medical students through an annual essay contest. The scholarship honors the journey of Dr. Jacqueline Youtsos, MD, a board-certified family medicine physician whose personal experience as a cancer patient during her medical residency reshaped her approach to compassionate, accessible care.

Dr. Jacqueline Youtsos established this scholarship to support future physicians who understand that resilience and empathy are as vital as clinical training. The program seeks students who have faced adversity, navigated the healthcare system themselves, or witnessed gaps in care for underserved communities.

Eligibility Criteria

The Dr. Jacqueline Youtsos Scholarship accepts applications from two groups of students:

  • Undergraduate students currently enrolled at an accredited U.S. college or university who are actively pursuing a pre-medical track or preparing for medical school.
  • Medical students currently enrolled in an accredited M.D. or D.O. program within the United States.

Applicants must submit an original, unpublished essay of 500 to 800 words responding to the following prompt:

“Dr. Jacqueline Youtsos faced a melanoma diagnosis during her medical residency, which deepened her understanding of what it means to be both a patient and a physician. Describe a challenge, personal health experience, or encounter with our healthcare system that shaped your own desire to practice medicine. How will you use that experience to provide more compassionate and accessible care to underserved communities?”

No minimum GPA is required. No letters of recommendation or transcripts are necessary. AI-generated submissions will be disqualified. Each student may submit only one entry per cycle.

Award Amount and Key Dates

  • Scholarship Award: $1,000 (one winner selected annually)
  • Submission Deadline: February 15, 2027
  • Winner Announcement: March 15, 2027

How to Apply

Interested students must email their essay as a PDF or Word document attachment to apply@drjacquelineyoutsos.com. The email subject line must read: “Scholarship Submission – [Applicant Full Name]” The email body must include the applicant’s full name, current school and year of study, status as an undergraduate (pre-med) or medical student, and a one-sentence confirmation that the essay is original work.

About the Dr. Jacqueline Youtsos Scholarship

Dr. Jacqueline Youtsos created this scholarship to invest in the next generation of physicians who prioritize equitable care. As a Family Medicine physician who founded ReNu Medical & Spa in a medically underserved region of Southeast Kansas, Dr. Jacqueline Youtsos remains one of the few practitioners for skin care in her area accepting both Medicare and Medicaid. She has served over 15,000 patients across five office locations.

Her own experience of undergoing melanoma removal while still a medical resident continues to inform her philosophy: that the best doctors are often shaped by their own trials. Dr. Jacqueline Youtsos speaks nationally and serves as a consultant for TreCeuticals. She lives in Kansas with her husband and daughters.

The scholarship carries no geographic restriction and is open to eligible students nationwide.

Media Contact
Company Name: Dr. Jacqueline Youtsos Scholarship
Contact Person: Dr. Jacqueline Youtsos
Email: Send Email
City: PITTSBURG
State: Florida
Country: United States
Website: https://drjacquelineyoutsosscholarship.com/

Gastroenteropancreatic Neuroendocrine Tumor Market Set for Strong Expansion Through 2036 Amid Rising Investment Interest – DelveInsight | RayzeBio, Merck Sharp & Dohme, Ipsen, Advanced Accelerator

The Key Gastroenteropancreatic Neuroendocrine Tumor Companies in the market include – ITM Isotope Technologies Munich, Camurus, RayzeBio, Merck Sharp & Dohme, Ipsen, Advanced Accelerator, Jiangsu HengRui Medicine, Camurus AB, Novartis, Tarveda Therapeutics, Progenics Pharmaceuticals, Pharmacyclics, and others.

 

DelveInsight’s “Gastroenteropancreatic Neuroendocrine Tumor Market Insights, Epidemiology, and Market Forecast-2036″ report offers an in-depth understanding of the Gastroenteropancreatic Neuroendocrine Tumor, historical and forecasted epidemiology as well as the Gastroenteropancreatic Neuroendocrine Tumor market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

Get a Free sample for the Gastroenteropancreatic Neuroendocrine Tumor Market Report:

https://www.delveinsight.com/report-store/gastroenteropancreatic-neuroendocrine-tumors-gep-nets-market

 

Some of the key facts of the Gastroenteropancreatic Neuroendocrine Tumor Market Report:

  • The Gastroenteropancreatic Neuroendocrine Tumor market size is anticipated to grow with a significant CAGR during the study period (2022-2036).

  • According to the Camurus AB’s 2026 presentation, results from the Phase III (SORENTO) trial are expected to be presented in 2026.

  • In November 2025, ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, announced that the U.S. Food and Drug Administration (FDA) has completed its filing review and accepted the company’s New Drug Application (NDA) for n.c.a. 177Lu-edotreotide (also known as ITM-11 or 177Lu-edotreotide). This proprietary, synthetic, targeted radiotherapeutic investigational agent is being developed by ITM for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The FDA has established a Prescription Drug User Fee Act (PDUFA) target action date of August 28, 2026.

  • In March 2025, US FDA approved cabozantinib (CABOMETYX, RayzeBio, Inc.) for adult and pediatric patients 12 years of age and older with previously treated, unresectable, locally advanced or metastatic, well-differentiated pancreatic neuroendocrine tumors (pNET) and well-differentiated extra-pancreatic neuroendocrine tumors (epNET).

  • Radioligand therapies and targeted agents are expected to remain key drivers of market expansion.

  • Emerging pipeline candidates focusing on receptor targeting, angiogenesis, and combination approaches such as surufatinib, and 177Lu-edotreotide are anticipated to increase competition and shape future treatment strategies.

  • The US contributed to the highest incident cases of NETs. The total incident cases of NETs in the United States in 2025 were 31,000.

  • According to the secondary search, net project, the incidence of malignant GEP-NET during 2000–2007 was 1.7 per 100,000 population per year in Europe, corresponding to an estimated 26,000 new cases.

  • As per the secondary sesrch, the annual incidence of the disease was 6.47 cases per 100,000 population, with an adjusted prevalence of 0.052%. The mean age at diagnosis was 58 ± 15 years, and the gender distribution was nearly equal, with 51% men and 49% women in Spain.

  • Surgical resection of the primary tumor was performed in 66% of patients. Histopathological grading showed that most tumors were well differentiated, with 73% classified as Grade 1 (G1), 22% as Grade 2 (G2), and 5% as Grade 3 (G3).

  • The most common primary tumor site was the pancreas (52%), followed by the jejunum–ileum (23%). At the time of diagnosis, 24% of patients presented with distant metastases, most frequently involving the liver (44%), peritoneum (25%), or multiple organs (22%). The majority of tumors were sporadic and non-functional.

  • Key Gastroenteropancreatic Neuroendocrine Tumor Companies: ITM Isotope Technologies Munich, Camurus, RayzeBio, Merck Sharp & Dohme, Ipsen, Advanced Accelerator, Jiangsu HengRui Medicine, Camurus AB, Novartis, Tarveda Therapeutics, Progenics Pharmaceuticals, Pharmacyclics, and others

  • Key Gastroenteropancreatic Neuroendocrine Tumor Therapies: SOMATULINE DEPOT, ITM-11, CAM2029, RYZ101, Lanreotide, arginine, lysine, Temozolomide (TMZ), Lutetium (177Lu) Oxodotreotide Injection, CAM2029, Everolimus, PEN-221, Lutathera, Ibrutinib, and others

  • The Gastroenteropancreatic Neuroendocrine Tumor epidemiology based on gender analyzed that the incidence of functional GEP-NET is more than that of nonfunctional GEP-NET in the United States

  • The Gastroenteropancreatic Neuroendocrine Tumor market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Gastroenteropancreatic Neuroendocrine Tumor pipeline products will significantly revolutionize the Gastroenteropancreatic Neuroendocrine Tumor market dynamics.

 

Gastroenteropancreatic Neuroendocrine Tumor Overview

Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) are a diverse group of tumors that arise from neuroendocrine cells in the gastrointestinal (GI) tract and pancreas. These cells have both endocrine and neural characteristics and are responsible for producing hormones that regulate various physiological functions.

 

To Know in detail about the Gastroenteropancreatic Neuroendocrine Tumor market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; GEP-NETs Market Forecast

 

Gastroenteropancreatic Neuroendocrine Tumor Epidemiology

The Gastroenteropancreatic Neuroendocrine Tumor epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2022 to 2036. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Gastroenteropancreatic Neuroendocrine Tumor Epidemiology Segmentation:

The Gastroenteropancreatic Neuroendocrine Tumor market report proffers epidemiological analysis for the study period 2022–2036 in the 7MM segmented into:

  • Total Incident Cases of GEP-NET in the 7MM

  • Grade-Specific Cases of GEP-NET in the 7MM

  • Tumor site-specific Cases of GEP-NET in the 7MM

  • Stage-specific Cases of GEP-NET in the 7MM

  • Symptom-specific Cases of GEP-NET in the 7MM

 

Download the report to understand which factors are driving GEP-NETs epidemiology trends @ Gastroenteropancreatic Neuroendocrine Tumor Epidemiology Forecast

 

Gastroenteropancreatic Neuroendocrine Tumor Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Gastroenteropancreatic Neuroendocrine Tumor market or expected to get launched during the study period. The analysis covers Gastroenteropancreatic Neuroendocrine Tumor market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Gastroenteropancreatic Neuroendocrine Tumor Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Gastroenteropancreatic Neuroendocrine Tumor Therapies and Key Companies

  • LUTATHERA (lutetium Lu 177 DOTATATE): Novartis

  • ITM-11 (n.c.a. 177Lu-edotreotide): ITM Isotope Technologies Munich

  • SOMATULINE DEPOT: Ipsen Biopharmaceuticals

  • ITM-11: ITM Isotope Technologies Munich

  • CAM2029: Camurus

  • RYZ101: RayzeBio

  • Lanreotide: Merck Sharp & Dohme

  • arginine/lysine: Advanced Accelerator

  • Temozolomide (TMZ): Ipsen

  • Lutetium (177Lu) Oxodotreotide Injection: Jiangsu HengRui Medicine

  • RYZ101: RayzeBio, Inc.

  • CAM2029: Camurus AB

  • Everolimus: Novartis

  • PEN-221: Tarveda Therapeutics

  • Lutathera: Progenics Pharmaceuticals

  • Ibrutinib: Pharmacyclics

 

Discover more about therapies set to grab major GEP-NETs market share @ Gastroenteropancreatic Neuroendocrine Tumor Treatment Market

 

Gastroenteropancreatic Neuroendocrine Tumor Market Strengths

  • GEP-NETs are often diagnosed at an early stage due to the hormonal symptoms they produce, allowing for timely intervention and better outcomes.

  • Treatment of GEP-NETs involves a multidisciplinary team of specialists, including oncologists, surgeons, and endocrinologists, which enhances the overall management of the disease.

 

Gastroenteropancreatic Neuroendocrine Tumor Market Opportunities

  • Continued research and development in targeted therapies, such as somatostatin analogs and molecular inhibitors, provide opportunities for more effective and personalized treatment approaches.

  • Participation in clinical trials can lead to the discovery of new treatment modalities and contribute to the improvement of patient outcomes.

 

Scope of the Gastroenteropancreatic Neuroendocrine Tumor Market Report

  • Study Period: 2022–2036

  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

  • Key Gastroenteropancreatic Neuroendocrine Tumor Companies: ITM Isotope Technologies Munich, Camurus, RayzeBio, Merck Sharp & Dohme, Ipsen, Advanced Accelerator, Jiangsu HengRui Medicine, Camurus AB, Novartis, Tarveda Therapeutics, Progenics Pharmaceuticals, Pharmacyclics, and others

  • Key Gastroenteropancreatic Neuroendocrine Tumor Therapies: SOMATULINE DEPOT, ITM-11, CAM2029, RYZ101, Lanreotide, arginine, lysine, Temozolomide (TMZ), Lutetium (177Lu) Oxodotreotide Injection, CAM2029, Everolimus, PEN-221, Lutathera, Ibrutinib, and others

  • Gastroenteropancreatic Neuroendocrine Tumor Therapeutic Assessment: Gastroenteropancreatic Neuroendocrine Tumor current marketed and Gastroenteropancreatic Neuroendocrine Tumor emerging therapies

  • Gastroenteropancreatic Neuroendocrine Tumor Market Dynamics: Gastroenteropancreatic Neuroendocrine Tumor market drivers and Gastroenteropancreatic Neuroendocrine Tumor market barriers

  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

  • Gastroenteropancreatic Neuroendocrine Tumor Unmet Needs, KOL’s views, Analyst’s views, Gastroenteropancreatic Neuroendocrine Tumor Market Access and Reimbursement

 

To know more about GEP-NETs companies working in the treatment market, visit @ Gastroenteropancreatic Neuroendocrine Tumor Clinical Trials and Therapeutic Assessment

 

Table of Contents

1. Gastroenteropancreatic Neuroendocrine Tumor Market Report Introduction

2. Executive Summary for Gastroenteropancreatic Neuroendocrine Tumor

3. SWOT analysis of Gastroenteropancreatic Neuroendocrine Tumor

4. Gastroenteropancreatic Neuroendocrine Tumor Patient Share (%) Overview at a Glance

5. Gastroenteropancreatic Neuroendocrine Tumor Market Overview at a Glance

6. Gastroenteropancreatic Neuroendocrine Tumor Disease Background and Overview

7. Gastroenteropancreatic Neuroendocrine Tumor Epidemiology and Patient Population

8. Country-Specific Patient Population of Gastroenteropancreatic Neuroendocrine Tumor

9. Gastroenteropancreatic Neuroendocrine Tumor Current Treatment and Medical Practices

10. Gastroenteropancreatic Neuroendocrine Tumor Unmet Needs

11. Gastroenteropancreatic Neuroendocrine Tumor Emerging Therapies

12. Gastroenteropancreatic Neuroendocrine Tumor Market Outlook

13. Country-Wise Gastroenteropancreatic Neuroendocrine Tumor Market Analysis (2022–2036)

14. Gastroenteropancreatic Neuroendocrine Tumor Market Access and Reimbursement of Therapies

15. Gastroenteropancreatic Neuroendocrine Tumor Market Drivers

16. Gastroenteropancreatic Neuroendocrine Tumor Market Barriers

17. Gastroenteropancreatic Neuroendocrine Tumor Appendix

18. Gastroenteropancreatic Neuroendocrine Tumor Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Gastroenteropancreatic Neuroendocrine Tumor Market Set for Strong Expansion Through 2036 Amid Rising Investment Interest – DelveInsight | RayzeBio, Merck Sharp & Dohme, Ipsen, Advanced Accelerator

Hereditary Transthyretin Amyloidosis (hATTR) Market Trends, Innovation, and Future Growth Outlook to 2036 – DelveInsight |Alnylam Pharma, Ionis Pharma, Novo Nordisk, AstraZeneca, Pfizer, Intellia

The Key Hereditary Transthyretin Amyloidosis Companies in the market include – Alnylam Pharmaceuticals, Ionis Pharmaceuticals, AstraZeneca, Pfizer, Intellia Therapeutics, Regeneron, Neurimmune, Alexion Pharmaceuticals, Novo Nordisk, Eidos Therapeutics, Corino Therapeutics, Prothena, Regeneron Pharmaceutical, and others.

 

DelveInsight’s “Hereditary Transthyretin Amyloidosis Market Insights, Epidemiology, and Market Forecast-2036″ report offers an in-depth understanding of the Hereditary Transthyretin Amyloidosis, historical and forecasted epidemiology as well as the Hereditary Transthyretin Amyloidosis market trends in the United States, EU4 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

Get a Free sample for the Hereditary Transthyretin Amyloidosis Market Report:

https://www.delveinsight.com/report-store/hereditary-transthyretin-amyloidosis-competitive-landscape-and-market

 

Some of the key facts of the Hereditary Transthyretin Amyloidosis Market Report:

  • The hereditary transthyretin amyloidosis (hATTR) market size is estimated to attain a value of nearly USD 3,000 million in 2025 and is anticipated to register a strong CAGR of 11% throughout the forecast period from 2026 to 2036.

  • According to estimates, the United States represented the largest share of the hATTR market in 2025, with a market size of nearly USD 2,000 million.

  • In March 2026, Intellia Therapeutics presentation, the Nex-Z ATTR program outlines a planned resumption of patient enrollment in the Phase III MAGNITUDE trial in ATTR-CM, resumption of patient enrollment in the Phase III MAGNITUDE-2 trial in ATTRv-PN, and expected completion of enrollment in MAGNITUDE-2 in the second half of 2026.

  • In February 2026, according to the Q4 and Full Year 2025 financial results of Alnylam Pharmaceuticals, the company plans to launch Nucresiran, a next-generation RNA silencer for Transthyretin Amyloidosis, with a potential launch timeline of 2028 for polyneuropathy and 2030 for cardiomyopathy indications.

  • As per the Ionis Pharmaceuticals Q4 2025 presentation, eplontersen is highlighted as a key asset, with an NDA submission expected in 2026 and a potential launch anticipated in 2027 for hATTR-CM.

  • In September 2025, Intellia Therapeutics, Inc. (NASDAQ: NTLA), a clinical-stage gene editing company advancing CRISPR-based therapies, announced longer-term follow-up data from its ongoing Phase 1 study of nexiguran ziclumeran (nex-z) for treating hereditary ATTR amyloidosis with polyneuropathy (ATTRv-PN). The findings were presented in an oral session on September 25 at the 5th International ATTR Amyloidosis Annual Meeting for Patients and Doctors in Baveno, Italy. The results were also published in the New England Journal of Medicine, and the presentation is available on the Scientific Publications & Presentations section of intelliatx.com.

  • In August 2025, Pfizer announced that it would discontinue VYNDAQEL (tafamidis meglumine) in the United States effective December 31, 2025, while confirming that VYNDAMAX (tafamidis) would continue to remain available for all eligible patients with a prescription.

  • In August 2025, Prothena Corporation announced that Novo Nordisk, during its Q2 2025 update, confirmed plans to advance coramitug, a potential first-in-class amyloid-clearing antibody, into a Phase III trial for ATTR amyloidosis with cardiomyopathy (ATTR-CM) in 2025. Originally developed by Prothena, coramitug was acquired by Novo Nordisk in July 2021.

  • In June 2025, Alnylam Pharmaceuticals announced that the European Commission (EC) has approved an expanded indication for AMVUTTRA (vutrisiran), an orphan RNAi therapy, for treating wild-type or hereditary transthyretin amyloidosis (ATTR-CM) in adult patients with cardiomyopathy.

  • In March 2025, Alnylam Pharmaceuticals announced that the US FDA approval of the supplemental New Drug Application (sNDA) for its RNAi therapeutic, AMVUTTRA (vutrisiran), for the treatment of the cardiomyopathy of wild-type or hATTR-CM in adults to reduce cardiovascular mortality, cardiovascular hospitalisations, and urgent heart failure visits. The approval expands the indication for AMVUTTRA, which now becomes the first and only therapeutic approved by the FDA for the treatment of ATTR-CM and the polyneuropathy of hATTR-PN in adults.

  • As per DelveInsight’s analysis, the US accounted for nearly 65% of the total diagnosed prevalent cases of hATTR in the 7MM in 2025, which is expected to increase further by 2036.

  • The secondary analysis indicates that hATTR generally affects both males and females equally, with no clear gender predominance. However, a possible parent-of-origin effect is suggested, as maternal inheritance may increase disease risk. In contrast, late-onset familial cases tend to show a higher prevalence among males.

  • A Japan-based study revealed that late-onset and nonendemic cases of hATTR are more common than previously recognised. Disease severity by ambulatory status showed 59% in stage 1, 19% in stage 2, and 14% in stage 3.

  • In 2025, France recorded the highest diagnosed prevalence of hATTR among other EU4 countries and the United Kingdom.

  • In the USA, the highest proportion of hATTR cases is seen in Familial Amyloid Polyneuropathy (FAP) at 45%, followed by mixed hATTR, while the lowest proportion is observed in Familial Amyloid Cardiomyopathy (FAC).

  • In the USA, the New York Heart Association (NYHA) classification of FAC shows that the majority of patients fall under Class II (60%), followed by Class III, while the lowest proportion is seen in Class IV.

  • Key Hereditary Transthyretin Amyloidosis Companies: Alnylam Pharmaceuticals, Ionis Pharmaceuticals, AstraZeneca, Pfizer, Intellia Therapeutics, Regeneron, Neurimmune, Alexion Pharmaceuticals, Novo Nordisk, Eidos Therapeutics, Corino Therapeutics, Prothena, Regeneron Pharmaceutical, and others

  • Key Hereditary Transthyretin Amyloidosis Therapies: Vutrisiran (AMVUTTRA), Eplontersen (WAINUA/WAINZUA), Vutrisiran (AMVUTTRA), Patisiran (ONPATTRO), Inotersen (TEGSEDI), Tafamidis (VYNDAMAX), Nexiguran ziclumeran (nex-z), Nucresiran, WAINUA (eplontersen), ONPATTRO (patisiran), TEGSEDI (inotersen), Nexiguran Ziclumeran, ALXN2220 (formerly NI006), Coramitug, Eplontersen, Acoramidis (AG 10), CRX-1008 (Tolcapone; SOM0226), PRX004, NTLA-2001, and others

  • The Hereditary Transthyretin Amyloidosis epidemiology based on gender analyzed that FAP is the most affected type-specific hATTR in the US

  • The Hereditary Transthyretin Amyloidosis market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Hereditary Transthyretin Amyloidosis pipeline products will significantly revolutionize the Hereditary Transthyretin Amyloidosis market dynamics.

 

Hereditary Transthyretin Amyloidosis Overview

Hereditary Transthyretin Amyloidosis (hATTR), also known as transthyretin amyloidosis or ATTRv amyloidosis, is a rare, inherited disorder characterized by the accumulation of abnormal deposits of a protein called transthyretin (TTR) in various tissues and organs throughout the body.

 

To Know in detail about the Hereditary Transthyretin Amyloidosis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Hereditary Transthyretin Amyloidosis Market Forecast

 

Hereditary Transthyretin Amyloidosis Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2022 to 2036. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Hereditary Transthyretin Amyloidosis Epidemiology Segmentation:

The Hereditary Transthyretin Amyloidosis market report proffers epidemiological analysis for the study period 2022–2036 in the 7MM segmented into:

  • Total Prevalent Cases of hATTR

  • Total Diagnosed Prevalent Cases of hATTR

  • Type-specific Diagnosed Prevalent Cases of hATTR

  • Stage-specific Diagnosed Prevalent Cases of FAP

  • Distribution of FAC Patients by New York Heart Association (NYHA) Criteria

 

Download the report to understand which factors are driving Hereditary Transthyretin Amyloidosis epidemiology trends @ Hereditary Transthyretin Amyloidosis Epidemiology Forecast

 

Hereditary Transthyretin Amyloidosis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Hereditary Transthyretin Amyloidosis market or expected to get launched during the study period. The analysis covers Hereditary Transthyretin Amyloidosis market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Hereditary Transthyretin Amyloidosis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Hereditary Transthyretin Amyloidosis Therapies and Key Companies

  • Vutrisiran (AMVUTTRA): Alnylam Pharmaceuticals

  • Eplontersen (WAINUA/WAINZUA): Ionis Pharmaceuticals and AstraZeneca

  • Vutrisiran (AMVUTTRA): Alnylam Pharmaceuticals

  • Patisiran (ONPATTRO): Alnylam Pharmaceuticals

  • Inotersen (TEGSEDI): Ionis Pharmaceuticals

  • Tafamidis (VYNDAMAX): Pfizer

  • Nexiguran ziclumeran (nex-z): Intellia Therapeutics and Regeneron

  • Nucresiran: Alnylam Pharmaceuticals

  • WAINUA (eplontersen): AstraZeneca/Ionis Pharmaceuticals

  • ONPATTRO (patisiran): Alnylam Pharmaceuticals

  • TEGSEDI (inotersen): Ionis Pharmaceuticals

  • Nexiguran Ziclumeran: Intellia Therapeutics

  • ALXN2220 (formerly NI006): Neurimmune/Alexion Pharmaceuticals

  • Coramitug: Novo Nordisk

  • CRX-1008 (Tolcapone; SOM0226): Corino Therapeutics

  • PRX004: Prothena/ Novo Nordisk

  • NTLA-2001: Intellia Therapeutics/Regeneron Pharmaceutical

  • Eplontersen: Ionis Pharmaceuticals/ AstraZeneca

  • Acoramidis (AG 10): Eidos Therapeutics

 

Discover more about therapies set to grab major Hereditary Transthyretin Amyloidosis market share @ Hereditary Transthyretin Amyloidosis Treatment Market

 

Hereditary Transthyretin Amyloidosis Market Strengths

  • The development and success of gene silencing therapies in hATTR amyloidosis is a breakthrough for adult-onset, neurodegenerative diseases.

  • The upcoming therapies with their novel mechanism of action hold potential to combat the unmet need faced by the patients with hATTR-CM and hATTR-PN and provide better treatment options to the patients.

  • The upcoming pipeline also includes a gene therapy based on CRISPR technology, which is currently in early phase of development. If this therapy gets approved, it could provide a cure for hATTR.

 

Hereditary Transthyretin Amyloidosis Market Opportunities

  • The unique mechanisms of action of inotersen and patisiran overcome many limitations of previous therapies for patients with hATTR.

  • Currently there is only one therapy approved for ATTR-CM in the 7MM, i.e., Vandaqel, this provides a window of opportunity for key players to develop therapies targeting ATTR-CM.

  • Additional evidence for current and emerging therapies for patients with hATTR offers much‐needed hope, along with a promise of better treatment, for this debilitating and life‐threatening disease.

 

Scope of the Hereditary Transthyretin Amyloidosis Market Report

  • Study Period: 2022–2036

  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

  • Key Hereditary Transthyretin Amyloidosis Companies: Alnylam Pharmaceuticals, Ionis Pharmaceuticals, AstraZeneca, Pfizer, Intellia Therapeutics, Regeneron, Neurimmune, Alexion Pharmaceuticals, Novo Nordisk, Eidos Therapeutics, Corino Therapeutics, Prothena, Regeneron Pharmaceutical, and others

  • Key Hereditary Transthyretin Amyloidosis Therapies: Vutrisiran (AMVUTTRA), Eplontersen (WAINUA/WAINZUA), Vutrisiran (AMVUTTRA), Patisiran (ONPATTRO), Inotersen (TEGSEDI), Tafamidis (VYNDAMAX), Nexiguran ziclumeran (nex-z), Nucresiran, WAINUA (eplontersen), ONPATTRO (patisiran), TEGSEDI (inotersen), Nexiguran Ziclumeran, ALXN2220 (formerly NI006), Coramitug, Eplontersen, Acoramidis (AG 10), CRX-1008 (Tolcapone; SOM0226), PRX004, NTLA-2001, and others

  • Hereditary Transthyretin Amyloidosis Therapeutic Assessment: Hereditary Transthyretin Amyloidosis current marketed and Hereditary Transthyretin Amyloidosis emerging therapies

  • Hereditary Transthyretin Amyloidosis Market Dynamics: Hereditary Transthyretin Amyloidosis market drivers and Hereditary Transthyretin Amyloidosis market barriers

  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

  • Hereditary Transthyretin Amyloidosis Unmet Needs, KOL’s views, Analyst’s views, Hereditary Transthyretin Amyloidosis Market Access and Reimbursement

 

To know more about Hereditary Transthyretin Amyloidosis companies working in the treatment market, visit @ Hereditary Transthyretin Amyloidosis Clinical Trials and Therapeutic Assessment

 

Table of Contents

1. Hereditary Transthyretin Amyloidosis Market Report Introduction

2. Executive Summary for Hereditary Transthyretin Amyloidosis

3. SWOT analysis of Hereditary Transthyretin Amyloidosis

4. Hereditary Transthyretin Amyloidosis Patient Share (%) Overview at a Glance

5. Hereditary Transthyretin Amyloidosis Market Overview at a Glance

6. Hereditary Transthyretin Amyloidosis Disease Background and Overview

7. Hereditary Transthyretin Amyloidosis Epidemiology and Patient Population

8. Country-Specific Patient Population of Hereditary Transthyretin Amyloidosis

9. Hereditary Transthyretin Amyloidosis Current Treatment and Medical Practices

10. Hereditary Transthyretin Amyloidosis Unmet Needs

11. Hereditary Transthyretin Amyloidosis Emerging Therapies

12. Hereditary Transthyretin Amyloidosis Market Outlook

13. Country-Wise Hereditary Transthyretin Amyloidosis Market Analysis (2022–2036)

14. Hereditary Transthyretin Amyloidosis Market Access and Reimbursement of Therapies

15. Hereditary Transthyretin Amyloidosis Market Drivers

16. Hereditary Transthyretin Amyloidosis Market Barriers

17. Hereditary Transthyretin Amyloidosis Appendix

18. Hereditary Transthyretin Amyloidosis Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Hereditary Transthyretin Amyloidosis (hATTR) Market Trends, Innovation, and Future Growth Outlook to 2036 – DelveInsight |Alnylam Pharma, Ionis Pharma, Novo Nordisk, AstraZeneca, Pfizer, Intellia

Duchenne Muscular Dystrophy Market Emerging as a High-Growth Healthcare Investment Space Through 2036 – DelveInsight | PTC Therapeutics, Sarepta Therapeutics, Taiho Pharma, Regenxbio, Fibrogen, Roche

The Key Duchenne Muscular Dystrophy Companies in the market include – Italfarmaco, Antisense Therapeutics, Sarepta Therapeutics, Santhera Pharmaceuticals/ReveraGen Biopharma, Pfizer, FibroGen, Capricor Therapeutics, Roche/Sarepta Therapeutics, Edgewise Therapeutics, Wave Life Sciences Ltd, PepGen, Ultragenyx Pharmaceutical, and others.

 

The Duchenne Muscular Dystrophy market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Duchenne Muscular Dystrophy pipeline products will significantly revolutionize the Duchenne Muscular Dystrophy market dynamics.

 

DelveInsight’s “Duchenne Muscular Dystrophy Market Insights, Epidemiology, and Market Forecast-2036″ report offers an in-depth understanding of the Duchenne Muscular Dystrophy, historical and forecasted epidemiology as well as the Duchenne Muscular Dystrophy market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

Get a Free sample for the Duchenne Muscular Dystrophy Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/duchenne-muscular-dystrophy-market

 

Some of the key facts of the Duchenne Muscular Dystrophy Market Report:

  • The Duchenne Muscular Dystrophy market size was valued at nearly USD 4,000 million in 2025 and is expected to expand at a robust CAGR of 11% between 2026 and 2036, driven by accelerating progress in therapy development and rising demand for advanced treatment options.

  • In March 2026, Sarepta Therapeutics provided an update on its ongoing regulatory interactions with the US FDA regarding VYONDYS 53 for the treatment of DMD. Sarepta requested a meeting with the FDA to discuss submitting an sNDA seeking conversion of the accelerated approval of VYONDYS 53 to traditional approvals. This request was supported by data from the ESSENCE confirmatory study; substantial, published real-world evidence supporting treatment; and the favorable safety profiles of both therapies. The Company intends to submit the sNDAs by the end of April.

  • In March 2026, Regenxbio announced new positive interim data from the Phase I/II AFFINITY DUCHENNE trial of RGX-202, a potential best-in-class gene therapy for DMD. Trial investigator Carolina Tesi-Rocha, M.D., Clinical Professor, Neurology, Stanford School of Medicine, Stanford Children’s Health, presented this data, including new functional, safety, biomarker, and cardiac MRI measures, at the Muscular Dystrophy Association (MDA) Clinical and Scientific Conference.

  • In January 2026, Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical-stage gene-editing company leveraging its proprietary ARCUS® platform to advance in vivo gene-editing therapies for diseases with significant unmet need, announced a business update outlining its strategic priorities for 2026. The update highlighted recent advancements across its two lead programs, upcoming clinical milestones, and a solid financial position that supports execution through key value-creating inflection points.

  • In January 2026, Solid Biosciences (SLDB) shares moved higher on Wednesday after the gene therapy company announced the completion of patient enrollment in its Phase 1/2 INSPIRE DUCHENNE trial evaluating its lead candidate SGT-003 in children with Duchenne muscular dystrophy, a progressive muscle-wasting disorder. The study had been planned to enroll 50–60 patients across clinical sites in the United States, Canada, Italy, and the United Kingdom.

  • In January 2026, Nxera Pharma Co. Ltd (TSE: 4565) announced that it has signed an exclusive licensing agreement with Santhera Pharmaceuticals Holding (SIX: SANN) covering the development, manufacturing, and commercialization of vamorolone for the treatment of Duchenne muscular dystrophy (DMD) in Japan, South Korea, Australia, and New Zealand. Vamorolone is already approved and marketed under the brand name AGAMREE® for DMD, a rare inherited neuromuscular disorder, in the United States, European Union, United Kingdom, and China.

  • In January 2026, Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company focused on developing innovative therapies for oncology and other areas with significant unmet medical need, announced that the FDA’s Office of Orphan Products Development (OOPD) has granted Orphan Drug Designation to (Z)-endoxifen for the treatment of Duchenne muscular dystrophy (DMD).

  • In October 2025, Regenxbio announced the completion of enrollment in the AFFINITY DUCHENNE pivotal trial of RGX-202, an investigational gene therapy for the treatment of DMD, as well as the successful production of the first batches intended for commercial supply.

  • In August 2025, The US Food and Drug Administration (FDA) has awarded Breakthrough Therapy designation to delpacibart zotadirsen (del-zota), an investigational therapy for Duchenne muscular dystrophy (DMD) in patients whose mutations are suitable for exon 44 skipping (DMD44). Developed by Avidity Biosciences, del-zota belongs to a new class of RNA-based treatments called Antibody Oligonucleotide Conjugates (AOCs™), which are engineered to enhance targeted delivery and potentially redefine therapeutic approaches for rare genetic disorders.

  • In July 2025, Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a leading company in precision genetic medicine for rare diseases, released a statement noting that the U.S. Food and Drug Administration (FDA) informally requested the company to voluntarily pause shipments of ELEVIDYS (delandistrogene moxeparvovec), its gene therapy for Duchenne muscular dystrophy, within the U.S. Sarepta stated that it became aware of this potential request earlier in the day through media coverage, at the same time as the general public and patient communities.

  • In May 2025, Satellos Bioscience’s investigational therapy SAT-3247 was found to be safe, well-tolerated, and showed early indications of improved muscle strength in five adults with Duchenne muscular dystrophy (DMD). In the initial part of the Phase 1 trial (NCT06565208), the oral small molecule, administered alongside steroids, demonstrated a favorable safety profile in healthy participants. Additionally, the drug’s pharmacokinetics—how it is absorbed, distributed, metabolized, and excreted—performed as anticipated in individuals with DMD.

  • In March 2025, REGENXBIO’s investigational gene therapy, RGX-202—an adeno-associated virus (AAV) vector-based treatment for Duchenne muscular dystrophy (DMD)—continues to show promising results. Data from two additional patients in the Phase 1/2 AFFINITY DUCHENNE trial (NCT05693142) reveal that the therapy consistently generates strong levels of microdystrophin expression.

  • In February 2025, Solid Biosciences reported that its gene therapy candidate, SGT-003, for Duchenne muscular dystrophy (DMD) achieved 110% microdystrophin expression in early clinical testing. The announcement of 90-day biopsy results from the Phase I/II Inspire DMD trial (NCT06138639) led to a sharp surge in the company’s stock, which rose by 78.66%—jumping from $4.03 on February 14 to $7.20 at market open on February 18. Among the first three of six enrolled patients, the observed gene expression suggests a promising potential to slow disease progression and support muscle function.

  • The total number of prevalent cases of Duchenne Muscular Dystrophy in the 7MM was around 32,000 in 2025.

  • The United States encompasses the highest prevalent population of Duchenne Muscular Dystrophy, around 17,500 in 2025.

  • Among EU4 and the UK, the UK accounts for the highest number of prevalent cases of Duchenne Muscular Dystrophy, whereas Spain accounts for the least number of prevalent cases.

  • In the US, the age group of 5-9 years accounted for the highest cases in 2025, followed by 10-14 years.

  • Most cases of Duchenne Muscular Dystrophy involve non-ambulatory individuals.

  • There are several comorbidities associated with Duchenne Muscular Dystrophy patients. In the United States, the maximum number of DMD patients affected with Scoliosis, followed by Attention-deficit hyperactivity disorder (ADHD) cases, was in 2025.

  • Key Duchenne Muscular Dystrophy Companies: Italfarmaco, Antisense Therapeutics, Sarepta Therapeutics, Santhera Pharmaceuticals/ReveraGen Biopharma, Pfizer, FibroGen, Capricor Therapeutics, Roche/Sarepta Therapeutics, Edgewise Therapeutics, Wave Life Sciences Ltd, PepGen, Ultragenyx Pharmaceutical, and others

  • Key Duchenne Muscular Dystrophy Therapies: Givinostat (ITF2357), ATL1102, SRP-9001, Vamorolone, PF06939926, Pamrevlumab, CAP-1002, Pamrevlumab, Delandistrogene moxeparvovec, EDG 5506, WVE N531, PGN EDO51, UX810, and others

  • The Duchenne Muscular Dystrophy epidemiology based on gender analyzed that Duchenne Muscular Dystrophy rarely affects females

  • In 2023, the age group with the highest number of cases was 5-9, totaling approximately 5,700 cases, followed by the 10-14 age group with around 5,000 cases. Duchenne muscular dystrophy (DMD) is uncommon in individuals above the age of 30.

  • The Duchenne Muscular Dystrophy market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Duchenne Muscular Dystrophy pipeline products will significantly revolutionize the Duchenne Muscular Dystrophy market dynamics.

 

Duchenne Muscular Dystrophy Overview

Duchenne muscular dystrophy (DMD) is a genetic disorder characterized by progressive muscle degeneration and weakness. It primarily affects boys, typically becoming evident in early childhood between the ages of 3 and 5.

 

To Know in detail about the Duchenne Muscular Dystrophy market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Duchenne Muscular Dystrophy Market Forecast

 

Duchenne Muscular Dystrophy Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2022 to 2036. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Duchenne Muscular Dystrophy Epidemiology Segmentation:

The Duchenne Muscular Dystrophy market report proffers epidemiological analysis for the study period 2022–2036 in the 7MM segmented into:

  • Total Prevalent Cases of Duchenne Muscular Dystrophy

  • Age-specific Cases of Duchenne Muscular Dystrophy

  • Ambulatory and Non-ambulatory Cases of Duchenne Muscular Dystrophy

  • Mutation-specific Cases of Duchenne Muscular Dystrophy

  • Associated Comorbidities in Duchenne Muscular Dystrophy

 

Download the report to understand which factors are driving Duchenne Muscular Dystrophy epidemiology trends @ Duchenne Muscular Dystrophy Epidemiology Forecast

 

Duchenne Muscular Dystrophy Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Duchenne Muscular Dystrophy market or expected to get launched during the study period. The analysis covers Duchenne Muscular Dystrophy market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Duchenne Muscular Dystrophy Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Duchenne Muscular Dystrophy Therapies and Key Companies

  • Deflazacort (EMFLAZA): PTC Therapeutics

  • Golodirsen (VYONDYS 53): Sarepta Therapeutics

  • EMFLAZA: PTC Therapeutics

  • EXONDYS 51: Sarepta Therapeutics

  • Pizuglanstat (TAS-205): Taiho Pharmaceutical

  • RGX 202: Regenxbio

  • Givinostat (ITF2357): Italfarmaco

  • ATL1102: Antisense Therapeutics

  • SRP-9001: Sarepta Therapeutics

  • Vamorolone: Santhera Pharmaceuticals/ReveraGen Biopharma

  • PF06939926: Pfizer

  • Pamrevlumab: FibroGen

  • CAP-1002: Capricor Therapeutics

  • Pamrevlumab: Fibrogen

  • Delandistrogene moxeparvovec: Roche/Sarepta Therapeutics

  • EDG 5506: Edgewise Therapeutics

  • WVE N531: Wave Life Sciences Ltd

  • PGN EDO51: PepGen

  • UX810: Ultragenyx Pharmaceutical

 

Discover more about therapies set to grab major Duchenne Muscular Dystrophy market share @ Duchenne Muscular Dystrophy Treatment Landscape

 

Duchenne Muscular Dystrophy Market Strengths

  • The pipeline of DMD is robust with the advent of several potential products in late-stage of clinical development.

  • Several new therapies have been approved for the treatment of DMD recently, even Japan has witnessed the launch of VILTEPSO now.

 

Duchenne Muscular Dystrophy Market Opportunities

  • Wider commercial opportunity for therapies such as Capricor’s CAP-1002 and Antisense’s ATL1102, which are specifically focusing on improving upper limb functions in DMD patients and are targeting a much larger patient segment when compared to the Exon-Skipping therapies.

 

Scope of the Duchenne Muscular Dystrophy Market Report

  • Study Period: 2022–2036

  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

  • Key Duchenne Muscular Dystrophy Companies: Italfarmaco, Antisense Therapeutics, Sarepta Therapeutics, Santhera Pharmaceuticals/ReveraGen Biopharma, Pfizer, FibroGen, Capricor Therapeutics, Fibrogen, Roche/Sarepta Therapeutics, Edgewise Therapeutics, Wave Life Sciences Ltd, PepGen, Ultragenyx Pharmaceutical, and others

  • Key Duchenne Muscular Dystrophy Therapies: Givinostat (ITF2357), ATL1102, SRP-9001, Vamorolone, PF06939926, Pamrevlumab, CAP-1002, Pamrevlumab, Delandistrogene moxeparvovec, EDG 5506, WVE N531, PGN EDO51, UX810, and others

  • Duchenne Muscular Dystrophy Therapeutic Assessment: Duchenne Muscular Dystrophy current marketed and Duchenne Muscular Dystrophy emerging therapies

  • Duchenne Muscular Dystrophy Market Dynamics: Duchenne Muscular Dystrophy market drivers and Duchenne Muscular Dystrophy market barriers

  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

  • Duchenne Muscular Dystrophy Unmet Needs, KOL’s views, Analyst’s views, Duchenne Muscular Dystrophy Market Access and Reimbursement

 

To know more about Duchenne Muscular Dystrophy companies working in the treatment market, visit @ Duchenne Muscular Dystrophy Clinical Trials and Therapeutic Assessment

 

Table of Contents

1. Duchenne Muscular Dystrophy Market Report Introduction

2. Executive Summary for Duchenne Muscular Dystrophy

3. SWOT analysis of Duchenne Muscular Dystrophy

4. Duchenne Muscular Dystrophy Patient Share (%) Overview at a Glance

5. Duchenne Muscular Dystrophy Market Overview at a Glance

6. Duchenne Muscular Dystrophy Disease Background and Overview

7. Duchenne Muscular Dystrophy Epidemiology and Patient Population

8. Country-Specific Patient Population of Duchenne Muscular Dystrophy

9. Duchenne Muscular Dystrophy Current Treatment and Medical Practices

10. Duchenne Muscular Dystrophy Unmet Needs

11. Duchenne Muscular Dystrophy Emerging Therapies

12. Duchenne Muscular Dystrophy Market Outlook

13. Country-Wise Duchenne Muscular Dystrophy Market Analysis (2022–2036)

14. Duchenne Muscular Dystrophy Market Access and Reimbursement of Therapies

15. Duchenne Muscular Dystrophy Market Drivers

16. Duchenne Muscular Dystrophy Market Barriers

17. Duchenne Muscular Dystrophy Appendix

18. Duchenne Muscular Dystrophy Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Duchenne Muscular Dystrophy Market Emerging as a High-Growth Healthcare Investment Space Through 2036 – DelveInsight | PTC Therapeutics, Sarepta Therapeutics, Taiho Pharma, Regenxbio, Fibrogen, Roche